🇺🇸 FDA
Patent

US 10167292

Benzodiazepines as bromodomain inhibitors

granted A61PA61P29/00A61P35/00

Quick answer

US patent 10167292 (Benzodiazepines as bromodomain inhibitors) held by Catalyst Therapeutics Pty Ltd. expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Catalyst Therapeutics Pty Ltd.
Grant date
Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P29/00, A61P35/00, A61P37/02, A61P43/00